By David Cassak
Given the relative closeness in size between the US and an aggregated European marketplace--and the clinical and regulatory importance Europe...
The Lonely World of European Device Start-Ups
Listen to this article
Because of a conservative clinical culture and a skittish venture community, medical-device company creation has lagged in Europe. The reasons for the lack of device company creation are several: a physician community that is not only not entrepreneurial, but often averse to capitalizing on commercial opportunities; a venture capital community unfamiliar with devices; and a lack of
Candid conversations with C-suite leaders.
More from Global Vision
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
- • By
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
- • By
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.